JavaScript NENÍ povolen !

This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.

MeSH
gastrointestinální nádory * diagnóza terapie MeSH
hepatocelulární karcinom * diagnóza terapie MeSH
lidé MeSH
nádory jater * diagnóza terapie MeSH
znalecký posudek MeSH
Check Tag
lidé MeSH
Publikační typ
časopisecké články MeSH
přehledy MeSH

Článek

Správná odpověď na kvíz [Answer to the quiz]

Bortlík, Martin, 1970-
Autor Autorita ORCID Gastroenterologické oddělení, Nemocnice České Budějovice, a. s

Gastroenterologie a hepatologie. 2023 ; 77 (6) : 544.

ISSN 1804-7874
Medvik
Zdroj

Anemický pacient

Anemic patient

MeSH
anemie * diagnóza etiologie MeSH
cholestáza diagnóza MeSH
dospělí MeSH
gastrointestinální nádory diagnóza MeSH
hypochromní anemie diagnóza etiologie MeSH
kolonoskopie metody MeSH
kolorektální nádory * diagnóza MeSH
lidé MeSH
ulcerózní kolitida komplikace MeSH
Check Tag
dospělí MeSH
lidé MeSH
mužské pohlaví MeSH
Publikační typ
kazuistiky MeSH

Článek

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology. 2022 ; 33 (1) : 20-33. [pub] 20210921

Ann Oncol
ISSN 1569-8041
Medvik
Zdroj

MeSH
gastrointestinální nádory * diagnóza epidemiologie terapie MeSH
gastrointestinální stromální tumory * diagnóza epidemiologie terapie MeSH
lidé MeSH
následné studie MeSH
sarkom * terapie MeSH
Check Tag
lidé MeSH
Publikační typ
práce podpořená grantem MeSH
směrnice pro lékařskou praxi MeSH

Článek

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

Virchows Archiv. 2022 ; 481 (2) : 201-212. [pub] 20220513

Virchows Arch
ISSN 1432-2307
Medvik
Zdroj

We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.

MeSH
adenokarcinom * diagnóza MeSH
diferenciální diagnóza MeSH
gastrointestinální nádory * diagnóza MeSH
imunohistochemie MeSH
keratin-17 MeSH
kolorektální nádory * diagnóza MeSH
lidé MeSH
nádorové biomarkery analýza MeSH
nádory slinivky břišní * diagnóza MeSH
nádory vaječníků * patologie MeSH
Check Tag
lidé MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH

Článek

Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group

Clinical colorectal cancer. 2022 ; 21 (3) : 188-197. [pub] 20220425

Clin Colorectal Cancer
ISSN 1938-0674
Medvik
Zdroj

Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.